CatalYm Presents Expanded Clinical and New Preclinical Data from
CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiati…
CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiati…
First Patient Enrolled in TURANDOT Study Evaluating Domatinostat in the Neoadjuvant Setting in Urothelial Carcinoma Comb…
Einschluss des ersten Patienten in die TURANDOT-Studie zur Evaluierung von Domatinostat im neoadjuvanten Setting beim Ur…
The global homeopathic products market has gained sudden popularity as the global population seeks alternative therapies…
. – Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy,…
4SC today announced the initiation of a second clinical collaboration with the Netherlands Cancer Institute (NKI) on a p…
Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations T ime Course…
Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Re…
Wissenschaftler des Hopp-Kindertumorzentrums Heidelberg (KiTZ) und des Deutschen Krebskonsortiums (DKTK) präsentieren di…
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral thera…